NYSE - Nasdaq Real Time Price USD

Rafael Holdings, Inc. (RFL)

2.0700

-0.1300

(-5.91%)

At close: June 13 at 4:00:02 PM EDT

2.0800

+0.01

+(0.48%)

After hours: June 13 at 7:59:30 PM EDT

Rafael Holdings Up 29%, Insider Buyers Are Up 61%

Last week, Rafael Holdings, Inc. ( NYSE:RFL ) insiders, who had purchased shares in the previous 12 months were...

Simply Wall St. 2 days ago

RFL
-5.91%

RFL-WS
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this monthNEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. “We are pleased

GlobeNewswire 3 days ago

RFL-WT

RFL
-5.91%

RFL-WS
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today the final results and closing of its $25.0 million rights offering (the “Rights Offering”). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscri

GlobeNewswire 10 days ago

RFL
-5.91%

RFL-WS

RFL-WT
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

NEWARK, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced rights offering. Under the rights offering, Rafael Holdings has distributed one (1) non-transferable subscription right for each share of Class B common stock or Class A common stock, or for each share of Class B common stock issuable upon exercise of the outstanding w

GlobeNewswire 25 days ago

RFL
-5.91%

RFL-WS

RFL-WT
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (the “Record Date”) will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025. Former holders of Cyclo Therapeutics, Inc. who did

GlobeNewswire last month

RFL
-5.91%

RFL-WS
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants (“Holders”) the opportunity to purchase additional shares of Rafael Holdings’ Class B common stock, par value $0.01 per share (“Class B Common Stock”), subject to the terms outlined below for an aggregate offering of $25 millio

GlobeNewswire last month

RFL-WT

RFL
-5.91%

RFL-WS
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advis

GlobeNewswire last month

RFL
-5.91%

RFL-WS

RFL-WT
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by sharehold

GlobeNewswire 2 months ago

RFL
-5.91%

CYTH

CYTHW
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. “We look forward to the upcoming shareholder vote on our pending merger with Cyclo Th

GlobeNewswire 3 months ago

CYTH

CYTHW

RFL
-5.91%
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™NEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. “We anticipate proceeding to a shareholder vote on our pending merger agreement with Cyclo Therapeutics, Inc. (Nasdaq: CYTH) in the first calendar quarter of 202

GlobeNewswire 5 months ago

RFL
-5.91%

CYTH

CYTHW
BioNexus Gene Lab Leads Our Top 3 US Penny Stocks

The U.S. stock market has been on a notable upswing, with the S&P 500 and Nasdaq reaching record highs following positive employment data that bolstered confidence in economic strength. For investors exploring beyond the well-known giants, penny stocks—typically smaller or newer companies—can offer intriguing opportunities despite their somewhat antiquated name. These stocks can provide surprising value when based on solid financials, and we will explore three examples that showcase potential...

Simply Wall St. 6 months ago

RFL
-5.91%

NEPH

BGLC
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical needNEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. “During fiscal 2024, we made significant progress on our strategy to advance our existing portfolio and to invest in, develop and commerc

GlobeNewswire 7 months ago

CYTH

CYTHW

RFL
-5.91%
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the

GlobeNewswire 9 months ago

CYTH

CYTHW

RFL
-5.91%
Rafael Holdings Third Quarter 2024 Earnings: US$1.36 loss per share (vs US$0.061 loss in 3Q 2023)

Rafael Holdings ( NYSE:RFL ) Third Quarter 2024 Results Key Financial Results Net loss: US$32.4m (loss widened by...

Simply Wall St. 11 months ago

RFL
-5.91%

Performance Overview

Return	RFL	S&P 500 (^GSPC)
YTD	+27.21%	+1.62%
1-Year	+41.82%	+10.00%
3-Year	+12.85%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rafael Holdings, Inc. (RFL)

Rafael Holdings Up 29%, Insider Buyers Are Up 61%

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

BioNexus Gene Lab Leads Our Top 3 US Penny Stocks

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings Third Quarter 2024 Earnings: US$1.36 loss per share (vs US$0.061 loss in 3Q 2023)

Performance Overview